Home » Newsletters » BioWorld

BioWorld

Sep. 24, 2008

View Archived Issues

BMS Goes Hostile, Takes Higher Offer to ImClone Shareholders

Bristol-Myers Squibb Co. hasn't given up trying to acquire Erbitux partner ImClone Systems Inc. (BioWorld Today) Read More

KaloBios Gets $20M Series D for Humaneered Antibodies

Addressing Publication Bias May Have Unintended Consequences

FTC: System-Gaming Loopholes Could Impair Any FOB Bill

Cellerant $13.5M Contract Will Fund Lead Program

Other News To Note

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...